Fungal Infections and New Biologic Therapies

被引：0
作者：
Snigdha Vallabhaneni
Tom M. Chiller
机构：
[1] National Center for Emerging and Zoonotic Diseases,Mycotic Diseases Branch, Division of Food, Water, and Environmental Diseases
[2] The Centers for Disease Control and Prevention,undefined
来源：
Current Rheumatology Reports | 2016年 / 18卷
关键词：
Biologics; TNF-alpha inhibitors; Anakinra; Abatacept; Rituximab; Ustekinumab; Tocilizumab; Tofacitinib; Vedolizumab; Secukinumab; Ixekizumab; Fungal infections; Histoplasmosis; Candidiasis; Cryptococcosis; Coccidioidomycosis; Aspergillosis; Incidence; Risk; Prevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The development of biologic therapies targeting proinflammatory mediators has led to significant advances in the treatment of immune-mediated inflammatory diseases (IMIDs). Blocking undesired inflammatory effects also has the potential to disrupt the body’s immune response and increase the risk for infections, including fungal infections. This review summarizes the published data on the frequency and risk for fungal infections among patients treated with biologics, with a focus on the newer therapies approved for use with IMIDs in the last 10 years. The use of biologics is associated with a small but important risk of fungal infections. Pneumocystis jirovecii pneumonia, histoplasmosis, and candidiasis are some of the most common fungal infections associated with biologics. Providers should be vigilant for fungal infection among patients taking biologics, be aware that biologic agents may alter the typical presentation of fungal infections, and take timely steps to diagnose and treat fungal infection to reduce resultant morbidity and mortality.
引用
收藏
相关论文
共 174 条
[31]  
Gershon SK(2015)Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) J Drugs Dermatol 66 742-9
[32]  
Bergstrom L(2013)Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up Br J Dermatol 73 990-28
[33]  
Yocum DE(2012)Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials J Am Acad Dermatol 367 1519-23
[34]  
Ampel NM(2014)Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Ann Rheum Dis 73 817-62
[35]  
Filler SG(2012)Ustekinumab induction and maintenance therapy in refractory Crohn’s disease N Engl J Med 50 552-7
[36]  
Yeaman MR(2014)Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS) Ann Rheum Dis 13 R141-61
[37]  
Sheppard DC(2011)Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials Rheumatology (Oxford) 22 122-21
[38]  
Salt E(2011)Integrated safety in tocilizumab clinical trials Arthritis Res Ther 159 253-23
[39]  
Wiggins AT(2012)Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab Mod Rheumatol 369 711-38
[40]  
Rayens MK(2013)Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial Ann Intern Med 93 e326-39
12345678910